Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to $385.0 million.

  • Prime Medicine's Liabilities and Shareholders Equity rose 15.69% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17.49%. This contributed to the annual value of $297.5 million for FY2024, which is 53.47% up from last year.
  • As of Q3 2025, Prime Medicine's Liabilities and Shareholders Equity stood at $385.0 million, which was up 37.99% from $279.0 million recorded in Q2 2025.
  • Prime Medicine's Liabilities and Shareholders Equity's 5-year high stood at $385.0 million during Q3 2025, with a 5-year trough of $193.9 million in Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $297.5 million (2024), whereas its average is $293.1 million.
  • Per our database at Business Quant, Prime Medicine's Liabilities and Shareholders Equity plummeted by 46.20% in 2023 and then soared by 53.47% in 2024.
  • Over the past 5 years, Prime Medicine's Liabilities and Shareholders Equity (Quarterly) stood at $301.9 million in 2021, then rose by 19.37% to $360.3 million in 2022, then slumped by 46.20% to $193.9 million in 2023, then surged by 53.47% to $297.5 million in 2024, then rose by 15.69% to $385.0 million in 2025.
  • Its last three reported values are $385.0 million in Q3 2025, $279.0 million for Q2 2025, and $328.2 million during Q1 2025.